Try a new search

Format these results:

Searched for:

person:mukhoa01

in-biosketch:true

Total Results:

37


Titration and discontinuation of semaglutide for weight management in commercially insured US adults

Xu, Yunwen; Carrero, Juan J; Chang, Alexander R; Inker, Lesley A; Zhang, Donglan; Mukhopadhyay, Amrita; Blecker, Saul B; Horwitz, Leora I; Grams, Morgan E; Shin, Jung-Im
OBJECTIVE:The objective of this study is to examine real-world dose titration patterns of semaglutide for weight management (Wegovy, Novo Nordisk A/S) in US adults and identify characteristics associated with early discontinuation. METHODS:We identified 15,811 commercially insured adults who started semaglutide for weight management (administrated through single-dose prefilled pens) between June 2021 and December 2023. We depicted dose-titration patterns over 5 months and identified factors associated with discontinuation using multivariable Cox regression. Sensitivity analyses examined patterns after supply shortage resolution (after October 2023). RESULTS:Most semaglutide users deviated from the recommended monthly dose-escalation schedule within the first 5 months. By the fifth month, nearly one-half (46%) had discontinued the treatment, with similar rates (48%) among those initiating after supply stabilization. Discontinuation was strongly associated with copayment amount, with rates increased from 41% in the lowest quintile ($1-$54 per month) to 51% in the highest quintile ($161-$1460 per month). Higher discontinuation rates were also associated with lower household income and education level. CONCLUSIONS:The deviations from the recommended dose-escalation schedule and high discontinuation rate among real-world semaglutide users indicate important challenges in the delivery of evidence-based care. Policy interventions that reduce financial barriers to the persistence of semaglutide are needed.
PMID: 40464214
ISSN: 1930-739x
CID: 5862372

Failure to Launch: Insights From Randomized Trials on Implementation Strategies for Guideline-Directed Therapies for Heart Failure

Rambarat, Paula; DeVore, Adam D; Bhatt, Ankeet S; Allen, Larry A; McIlvennan, Colleen K; Cotter, Gad; Mukhopadhyay, Amrita; Ahmad, Tariq; Ahmad, Faraz S; Psotka, Mitchell A
There is a pressing need to translate evidence for heart failure (HF) therapies into contemporary practice. Medications that improve HF morbidity and mortality remain underused because of complex barriers at multiple levels across the health care ecosystem. High-quality implementation trials demonstrate that specific interventions can increase prescription, intensification, and persistence of HF medication. However, evidence-based interventions have not been widely implemented across health care organizations in the United States. This review explores 5 key strategies-patient activation, audit and feedback, rapid intensive initiation of medical therapy, virtual care teams, and clinical decision support tools-and discusses barriers to their widespread adoption. Although some barriers are specific to an intervention, others stem from systemic limitations among health care organizations and the health policy landscape. Using lessons learned from recent trials, this review also highlights future investigations needed to address these barriers, encourages uptake of successful implementation strategies, and discusses common approaches that should be abandoned.
PMID: 40467171
ISSN: 2213-1787
CID: 5862492

Patient portal messaging to address delayed follow-up for uncontrolled diabetes: a pragmatic, randomised clinical trial

Nagler, Arielle R; Horwitz, Leora Idit; Ahmed, Aamina; Mukhopadhyay, Amrita; Dapkins, Isaac; King, William; Jones, Simon A; Szerencsy, Adam; Pulgarin, Claudia; Gray, Jennifer; Mei, Tony; Blecker, Saul
IMPORTANCE/OBJECTIVE:Patients with poor glycaemic control have a high risk for major cardiovascular events. Improving glycaemic monitoring in patients with diabetes can improve morbidity and mortality. OBJECTIVE:To assess the effectiveness of a patient portal message in prompting patients with poorly controlled diabetes without a recent glycated haemoglobin (HbA1c) result to have their HbA1c repeated. DESIGN/METHODS:A pragmatic, randomised clinical trial. SETTING/METHODS:A large academic health system consisting of over 350 ambulatory practices. PARTICIPANTS/METHODS:Patients who had an HbA1c greater than 10% who had not had a repeat HbA1c in the prior 6 months. EXPOSURES/METHODS:A single electronic health record (EHR)-based patient portal message to prompt patients to have a repeat HbA1c test versus usual care. MAIN OUTCOMES/RESULTS:The primary outcome was a follow-up HbA1c test result within 90 days of randomisation. RESULTS:The study included 2573 patients with a mean (SD) HbA1c of 11.2%. Among 1317 patients in the intervention group, 24.2% had follow-up HbA1c tests completed within 90 days, versus 21.1% of 1256 patients in the control group (p=0.07). Patients in the intervention group were more likely to log into the patient portal within 60 days as compared with the control group (61.2% vs 52.3%, p<0.001). CONCLUSIONS:Among patients with poorly controlled diabetes and no recent HbA1c result, a brief patient portal message did not significantly increase follow-up testing but did increase patient engagement with the patient portal. Automated patient messages could be considered as a part of multipronged efforts to involve patients in their diabetes care.
PMID: 40348403
ISSN: 2044-5423
CID: 5843792

Association of Patient Cost-Sharing With Adherence to GLP-1a and Adverse Health Outcomes

Zhang, Donglan; Gencerliler, Nihan; Mukhopadhyay, Amrita; Blecker, Saul; Grams, Morgan E; Wright, Davene R; Wang, Vivian Hsing-Chun; Rajan, Anand; Butt, Eisha; Shin, Jung-Im; Xu, Yunwen; Chhabra, Karan R; Divers, Jasmin
OBJECTIVE:To examine the associations between patient out-of-pocket (OOP) costs and nonadherence to glucagon-like peptide 1 receptor agonists (GLP-1a), and the consequent impact on adverse outcomes, including hospitalizations and emergency department (ED) visits. RESEARCH DESIGN AND METHODS/METHODS:This retrospective cohort study used MarketScan Commercial data (2016-2021). The cohort included nonpregnant adults aged 18-64 years with type 2 diabetes who initiated GLP-1a therapy. Participants were continuously enrolled in the same private insurance plan for 6 months before the prescription date and 1 year thereafter. Exposures included average first 30-day OOP costs for GLP-1a, categorized into quartiles (lowest [Q1] to highest [Q4]). Primary outcomes were the annual proportion of days covered (PDC) for GLP-1a and nonadherence, defined as PDC <0.8. Secondary outcomes included diabetes-related and all-cause hospitalizations and ED visits 1 year post-GLP-1a initiation. RESULTS:Among 61,907 adults who initiated GLP-1a, higher 30-day OOP costs were associated with decreased adherence. Patients in the highest OOP cost quartile (Q4: $80-$3,375) had significantly higher odds of nonadherence (odds ratio [OR]1.25; 95% CI 1.19-1.31) compared with those in Q1 ($0-$21). Nonadherence was linked to increased incidence rates of diabetes-related hospitalizations or ED visits (incidence rate ratio [IRR] 1.86; 95% CI 1.43-2.42), cumulative length of hospitalization (IRR 1.56; 95% CI 1.41-1.72), all-cause ED visits (IRR 1.38; 95% CI 1.32-1.45), and increased ED-related costs ($69.81, 95% CI $53.54-$86.08). CONCLUSIONS:Higher OOP costs for GLP-1a were associated with reduced adherence and increased rates of adverse outcomes among type 2 diabetes patients.
PMID: 40202527
ISSN: 1935-5548
CID: 5823882

Approach to Estimating Adherence to Heart Failure Medications Using Linked Electronic Health Record and Pharmacy Data

Blecker, Saul; Zhao, Yunan; Li, Xiyue; Kronish, Ian M; Mukhopadhyay, Amrita; Stokes, Tyrel; Adhikari, Samrachana
BACKGROUND:Medication non-adherence, which is common in chronic diseases such as heart failure, is often estimated using proportion of days covered (PDC). PDC is typically calculated using medication fill information from pharmacy or insurance claims data, which lack information on when medications are prescribed. Many electronic health records (EHRs) have prescription and pharmacy fill data available, enabling enhanced PDC assessment that can be utilized in routine clinical care. OBJECTIVE:To describe our approach to calculating PDC using linked EHR-pharmacy data and to compare to PDC calculated using pharmacy-only data for patients with heart failure. METHODS:We performed a retrospective cohort study of adult patients with heart failure who were prescribed guideline-directed medical therapy (GDMT) and seen in a large health system. Using linked EHR-pharmacy data, we estimated medication adherence by PDC as the percent of days in which a patient possessed GDMT based on medication pharmacy fills over the number of days the prescription order was active. We also calculated PDC using pharmacy-only data, calculated as medications possessed over days with continued medication fills. We compared these two approaches for days observed and PDC using a paired t-test. RESULTS:Among 33,212 patients with heart failure who were prescribed GDMT, 2226 (6.7%) never filled their medications, making them unavailable in the assessment of PDC using pharmacy-only data (n = 30,995). Linked EHR-pharmacy data had slightly longer days observed for PDC assessment (164.7 vs. 163.4 days; p < 0.001) and lower PDC (78.5 vs. 90.6, p < 0.001) as compared to assessment using pharmacy-only data. CONCLUSIONS:Linked EHR-pharmacy data can be used to identify patients who never fill their prescriptions. Estimating adherence using linked EHR-pharmacy data resulted in a lower mean PDC as compared to estimates using pharmacy-only data.
PMID: 39585579
ISSN: 1525-1497
CID: 5803832

Association Between Cardiometabolic Comorbidity Burden and Outcomes in Heart Failure

Hamo, Carine E; Li, Xiyue; Ndumele, Chiadi E; Mukhopadhyay, Amrita; Adhikari, Samrachana; Blecker, Saul
BACKGROUND:Cardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heart failure (HF). We aimed to examine the association between severity of cardiometabolic comorbidities and hospitalization in patients with HF. METHODS: RESULTS: CONCLUSIONS:Greater cardiometabolic comorbidity burden was associated with increased risk of all-cause hospitalization in HF. This reinforces the role for targeting severely uncontrolled cardiometabolic comorbidities to reduce morbidity in HF.
PMID: 39846294
ISSN: 2047-9980
CID: 5783512

Association Between Video-Based Telemedicine Visits and Medication Adherence Among Patients With Heart Failure: Retrospective Cross-Sectional Study

Zheng, Yaguang; Adhikari, Samrachana; Li, Xiyue; Zhao, Yunan; Mukhopadhyay, Amrita; Hamo, Carine E; Stokes, Tyrel; Blecker, Saul
BACKGROUND/UNASSIGNED:Despite the exponential growth in telemedicine visits in clinical practice due to the COVID-19 pandemic, it remains unknown if telemedicine visits achieved similar adherence to prescribed medications as in-person office visits for patients with heart failure. OBJECTIVE/UNASSIGNED:Our study examined the association between telemedicine visits (vs in-person visits) and medication adherence in patients with heart failure. METHODS/UNASSIGNED:This was a retrospective cross-sectional study of adult patients with a diagnosis of heart failure or an ejection fraction of ≤40% using data between April 1 and October 1, 2020. This period was used because New York University approved telemedicine visits for both established and new patients by April 1, 2020. The time zero window was between April 1 and October 1, 2020, then each identified patient was monitored for up to 180 days. Medication adherence was measured by the mean proportion of days covered (PDC) within 180 days, and categorized as adherent if the PDC was ≥0.8. Patients were included in the telemedicine exposure group or in-person group if all encounters were video visits or in-person office visits, respectively. Poisson regression and logistic regression models were used for the analyses. RESULTS/UNASSIGNED:A total of 9521 individuals were included in this analysis (telemedicine visits only: n=830 in-person office visits only: n=8691). Overall, the mean age was 76.7 (SD 12.4) years. Most of the patients were White (n=6996, 73.5%), followed by Black (n=1060, 11.1%) and Asian (n=290, 3%). Over half of the patients were male (n=5383, 56.5%) and over half were married or living with partners (n=4914, 51.6%). Most patients' health insurance was covered by Medicare (n=7163, 75.2%), followed by commercial insurance (n=1687, 17.7%) and Medicaid (n=639, 6.7%). Overall, the average PDC was 0.81 (SD 0.286) and 71.3% (6793/9521) of patients had a PDC≥0.8. There was no significant difference in mean PDC between the telemedicine and in-person office groups (mean 0.794, SD 0.294 vs mean 0.812, SD 0.285) with a rate ratio of 0.99 (95% CI 0.96-1.02; P=.09). Similarly, there was no significant difference in adherence rates between the telemedicine and in-person office groups (573/830, 69% vs 6220/8691, 71.6%), with an odds ratio of 0.94 (95% CI 0.81-1.11; P=.12). The conclusion remained the same after adjusting for covariates (eg, age, sex, race, marriage, language, and insurance). CONCLUSIONS/UNASSIGNED:We found similar rates of medication adherence among patients with heart failure who were being seen via telemedicine or in-person visits. Our findings are important for clinical practice because we provide real-world evidence that telemedicine can be an approach for outpatient visits for patients with heart failure. As telemedicine is more convenient and avoids transportation issues, it may be an alternative way to maintain the same medication adherence as in-person visits for patients with heart failure.
PMCID:11637490
PMID: 39637412
ISSN: 2561-1011
CID: 5763802

Shortfalls in Follow-up Albuminuria Quantification After an Abnormal Result on a Urine Protein Dipstick Test

Xu, Yunwen; Shin, Jung-Im; Wallace, Amelia; Carrero, Juan J; Inker, Lesley A; Mukhopadhyay, Amrita; Blecker, Saul B; Horwitz, Leora I; Grams, Morgan E; Chang, Alexander R
PMID: 39348706
ISSN: 1539-3704
CID: 5738782

Assessment of Revascularization Preferences with Best-Worst Scaling Among Patients with Ischemic Heart Disease

Mukhopadhyay, Amrita; Dickson, Victoria Vaughan; Langford, Aisha; Spertus, John A; Bangalore, Sripal; Zhang, Yan; Tarpey, Thaddeus; Hochman, Judith; Katz, Stuart D
PMID: 39423941
ISSN: 1532-8414
CID: 5718902

Cardiologist Perceptions on Automated Alerts and Messages To Improve Heart Failure Care

Maidman, Samuel D; Blecker, Saul; Reynolds, Harmony R; Phillips, Lawrence M; Paul, Margaret M; Nagler, Arielle R; Szerencsy, Adam; Saxena, Archana; Horwitz, Leora I; Katz, Stuart D; Mukhopadhyay, Amrita
Electronic health record (EHR)-embedded tools are known to improve prescribing of guideline-directed medical therapy (GDMT) for patients with heart failure. However, physicians may perceive EHR tools to be unhelpful, and may be therefore hesitant to implement these in their practice. We surveyed cardiologists about two effective EHR-tools to improve heart failure care, and they perceived the EHR tools to be easy to use, helpful, and improve the overall management of their patients with heart failure.
PMID: 39423991
ISSN: 1097-6744
CID: 5718912